Research map: Tumour-absorbed dose and efficacy of peptide receptor radionuclide therapy with [90Y]Y-DOTATOC in patients with refractory meningioma: a single-centre experience

Back to the article

Papers in this map

  1. MIRD Pamphlet No. 21: A Generalized Schema for Radiopharmaceutical Dosimetry—Standardization of Nomenclature · Wesley Emmett Bolch · 2009 · 912 citations · Cited by this paper
  2. Real-world evaluation of [177Lu]Lu-PSMA-617 RLT in post-taxane mCRPC: feasibility and safety of individualized treatment in a challenging cohort · 2026 · Related
  3. EANO guideline on the diagnosis and management of meningiomas · Roland Goldbrunner · 2021 · 767 citations · Cited by this paper
  4. Whole-body TSPO-PET reveals stage-dependent disruption of systemic immune organ interactions in glioblastoma · 2026 · Related
  5. MIRD Pamphlet No. 26: Joint EANM/MIRD Guidelines for Quantitative 177 Lu SPECT Applied for Dosimetry of Radiopharmaceutical Therapy · Michael H. Ljungberg · 2015 · 374 citations · Cited by this paper
  6. Evaluation of treatment efficacy of the 161Tb- and 177Lu-Labeled GRPR antagonists AMTG and RM2 in a mouse model of prostate cancer · 2026 · Related
  7. Meningioma: A Review of Epidemiology, Pathology, Diagnosis, Treatment, and Future Directions · Christian T. Ogasawara · 2021 · 324 citations · Cited by this paper
  8. From image reconstruction to clinical prognosis: A comprehensive analysis of centiloid-based amyloid PET assessment · 2026 · Related
  9. Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group · Raymond Y. Huang · 2018 · 215 citations · Cited by this paper
  10. [18F]FDG PET during immunotherapy: mind the gap between evidence, imaging guidelines, and oncology practice · 2026 · Related
  11. Peptide receptor radionuclide therapy with 90Y-DOTATOC in recurrent meningioma · Mirco Bartolomei · 2009 · 151 citations · Cited by this paper
  12. CSF proteomic pathway alterations and caudate dopamine transporter deficits predict cognitive vulnerability in early Parkinson’s disease · 2026 · Related
  13. Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma · Michael Christoph Kreissl · 2012 · 101 citations · Cited by this paper
  14. Skeletal muscle radiodensity as an automated survival predictor in men with metastatic castration-resistant prostate cancer undergoing PSMA-targeted radioligand therapy · 2026 · Related
  15. Emerging systemic treatment options in meningioma · Maximilian Johannes Mair · 2022 · 84 citations · Cited by this paper
  16. In vivo multimodal PET/MRI imaging and plasma biomarkers implicate glymphatic dysfunction linking neuroinflammation to tau pathology in the early Alzheimer’s disease continuum · 2026 · Related
  17. Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor ligands: version 1.0 · Nathalie L. Albert · 2024 · 70 citations · Cited by this paper
  18. Prospective comparison of [68Ga]Ga-FAPI-04 PET/MRI, [18F]FDG PET/CT, and contrast-enhanced MRI for predicting pathologic complete response after neoadjuvant chemotherapy in breast cancer · 2026 · Related
  19. 90 Y-DOTATOC as a Therapeutic Option for Complex Recurrent or Progressive Meningiomas · Karine Gerster-Gilliéron · 2015 · 68 citations · Cited by this paper
  20. Evaluation of the SSTR2-targeted Radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as Imaging Biomarker in Patients with Intracranial Meningioma · Sylvia Christine Kurz · 2023 · 56 citations · Cited by this paper
  21. PET SUV correlates with radionuclide uptake in peptide receptor therapy in meningioma · Heribert Hänscheid · 2012 · 55 citations · Cited by this paper
  22. Evaluating diagnostic accuracy and determining optimal diagnostic thresholds of different approaches to [68Ga]-DOTATATE PET/MRI analysis in patients with meningioma · Sean Kim · 2022 · 48 citations · Cited by this paper
  23. Radiolabelling of peptides for PET, SPECT and therapeutic applications using a fully automated disposable cassette system · Miloš Petřík · 2011 · 45 citations · Cited by this paper
  24. Efficacy and safety of peptide receptor radionuclide therapy with [177Lu]Lu-DOTA-TATE in 15 patients with progressive treatment-refractory meningioma · Noémie S. Minczeles · 2022 · 35 citations · Cited by this paper
  25. Radioligand therapies in meningioma: Evidence and future directions · Maximilian Johannes Mair · 2024 · 26 citations · Cited by this paper
  26. Peptide Receptor Radionuclide Therapy in Advanced Refractory Meningiomas: Efficacy and Toxicity in a Long Follow-up · Stefano Severi · 2024 · 25 citations · Cited by this paper
  27. Correlation between 99mTc-HYNIC-octreotide SPECT/CT somatostatin receptor scintigraphy and pathological grading of meningioma · Shengjun Wang · 2013 · 22 citations · Cited by this paper
  28. Theragnostic Use of Radiolabelled Dota-Peptides in Meningioma: From Clinical Demand to Future Applications · Riccardo Laudicella · 2019 · 22 citations · Cited by this paper
  29. Peptide receptor radionuclide therapy with somatostatin analogs beyond gastroenteropancreatic neuroendocrine tumors · Giulia Santo · 2025 · 18 citations · Cited by this paper
  30. P01.02 Biological role and therapeutic targeting of TGF-β3 in glioblastoma · Katharina Seystahl · 2016 · 13 citations · Cited by this paper
  31. 177Lu-labeled somatostatin receptor targeted radionuclide therapy dosimetry in meningioma: a systematic review · Caroline Boursier · 2024 · 12 citations · Cited by this paper
  32. Peptide Receptor Radionuclide Therapy in Patients with Advanced, Recurrent or Progressive Meningioma: An Updated Systematic Review and Meta-Analysis · Barbara Muoio · 2025 · 9 citations · Cited by this paper
  33. Do we need dosimetry for the optimization of theranostics in CNS tumors? · Francesco Cicone · 2024 · 7 citations · Cited by this paper
  34. Long-term Efficacy, Survival, and Toxicity of Peptide Receptor Radionuclide Therapy in Patients With Refractory Meningioma · Jingjing Zhang · 2025 · 7 citations · Cited by this paper
  35. Joint EANM, IAEA, and SNMMI practical guidance on somatostatin receptor-targeted radionuclide therapy of neuroendocrine tumours · Lisa Bodei · 2026 · 6 citations · Cited by this paper

Source: OpenAlex (CC0)